Drug Interactions between chloramphenicol and ixazomib
This report displays the potential drug interactions for the following 2 drugs:
- chloramphenicol
- ixazomib
Interactions between your drugs
chloramphenicol ixazomib
Applies to: chloramphenicol and ixazomib
GENERALLY AVOID: Coadministration of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia, and bone marrow depression) have been reported after short-term and long-term systemic therapy with chloramphenicol.
MANAGEMENT: Concurrent use of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis, such as sulfonamides, nucleoside reverse transcriptase inhibitors, procainamide, phenylbutazone, clozapine, and depot formulations of antipsychotic drugs, should be avoided.
References (4)
- (2002) "Product Information. Chloromycetin (chloramphenicol)." Parke-Davis
- (2022) "Product Information. Chloromycetin (chloramphenicol)." Pfizer Canada Inc
- (2015) "Product Information. Chloromycetin Succinate (chloramphenicol)." Link Medical Products Pty Ltd T/A Link Pharmaceuticals
- (2023) "Product Information. Chloramphenicol (chloramphenicol)." Eramol (UK) Ltd
Drug and food interactions
ixazomib food
Applies to: ixazomib
ADJUST DOSING INTERVAL: Food may reduce the oral bioavailability of ixazomib. A food effect study found that administration of a single 4 mg dose of ixazomib with a high-fat meal decreased ixazomib peak plasma concentration (Cmax) by 69% and systemic exposure (AUC) by 28%.
MANAGEMENT: Ixazomib should be taken at least one hour before or two hours after eating. On days when both ixazomib and dexamethasone are administered, advise patients to separate dosing times, since dexamethasone should be taken with food while ixazomib should be taken on an empty stomach.
References (1)
- (2015) "Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.